Formulation Development
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
Silo Pharma, Inc. recently announced positive results from its non-GLP small animal dose-ranging study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress…
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics & Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
Dyadic International, Inc. recently announced its Dutch subsidiary, Dyadic Nederland BV has entered into a strategic partnership agreement and collaboration with Rabian BV, a Dutch…
Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury
Arch Biopartners Inc. recently announced it had a pre-investigational new drug application (PIND) meeting with the US FDA Division of Cardiovascular and Renal Products (DCRP)…
Bio-Rad Launches Vericheck ddPCR Replication Competent Lentivirus & Replication Competent AAV Kits for Cell & Gene Therapy Production
Bio-Rad Laboratories, Inc. recently announced the launch of the Vericheck ddPCR Replication Competent Lentivirus Kit and the Vericheck ddPCR Replication Competent AAV Kit. The kits provide rapid….
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination With Bevacizumab in Advanced Ovarian Cancer
IMUNON, Inc. recently announced Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating…
ABVC's New Horizon for Oncology & Hematology Aims at Cancer Market of Several Hundred Billion Dollars
ABVC BioPharma, Inc. recently provided an update on its development of combination therapy for the treatment of cancer and immunity booster dietary supplements. The company is currently marketing….
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration With Neurocrine Biosciences, Triggering Milestone Payment
Voyager Therapeutics, Inc. recently announced the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the Friedreich’s ataxia (FA) program. The candidate combines….
MoonLake Immunotherapeutics Announces Positive Feedback From FDA & EMA on Regulatory Path for Phase 3 Program
MoonLake Immunotherapeutics recently announced the successful outcome of its end-of-Phase 2 interactions with the US FDA as well as positive feedback from its interactions with…
Lirum Therapeutics Presents Positive Data on Novel Clinical-Stage Targeted Therapy
Lirum Therapeutics, Inc. recently announced today it presented positive data on LX-101, a novel clinical-stage targeted therapy directed to the insulin growth factor-1 receptor (IGF-1R),…
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose Cohorts of Phase 1 Clinical Study of BT-600
Biora Therapeutics, Inc. recently announced completion of the single-ascending dose (SAD) cohorts for its Phase 1, first-in-human clinical study of BT-600 in healthy adult volunteers.…
LIXTE Biotechnology Enters Exclusive Immune Oncology Patent License Agreement With NINDS & NCI
LIXTE Biotechnology Holdings, Inc. recently announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National…
Tenaya Therapeutics Announces Preclinical HDAC6 Inhibitor Data for Heart Failure With Preserved Ejection Fraction
Tenaya Therapeutics, Inc. recently announced the publication of preclinical research related to Tenaya’s small molecule inhibitors of histone deacetylase 6 (HDAC6), including TN-301, in the…
Curia Appoints New Vice President, Biologics
Curia recently announced it has appointed Steve Lavezoli as Vice President of Biologics effective February 26. Lavezoli will lead Curia’s biologics division, overseeing its discovery,…
Jubilant HollisterStier Opens Third Manufacturing Line
Jubilant HollisterStier recently celebrated the opening of its third sterile fill finish manufacturing line and broke ground on the next phase of its facility expansion in Spokane, WA…..
MAIA Biotechnology Completes Enrollment in Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. recently announced enrollment is now complete in its Phase 2 THIO-101 go-to-market clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor…
Tarsus Announces Positive Topline Results From Phase 2a Proof-of-Concept Trial Evaluating TP-05 for the Prevention of Lyme Disease
TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxis….
Avenue Therapeutics Announces First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
Avenue Therapeutics, Inc. recently announced the publication of preclinical in vivo data in Drug Development Research highlighting BAER-101’s full suppression of seizure activity using the…
Polpharma Biologics’ Investigational Biosimilar Shows PK/PD Comparability to Inflammatory Bowel Disease Blockbuster Entyvio
Polpharma Biologics recently announced topline results demonstrating the pharmacokinetic (PK) and pharmacodynamic (PD) comparability of its biosimilar candidate PB016 to its reference drug, Entyvio (vedolizumab). Results…
Cresset Announces Global Collaboration With Enamine on New Virtual Screening Drug Discovery Technology
Cresset recently announced a collaboration with Enamine, the world’s leading provider of chemical building blocks and drug discovery services to develop innovative….
Eton Pharmaceuticals Awarded US Patent for Proprietary Hydrocortisone Oral Liquid Formulation
Eton Pharmaceuticals recently announced the United States Patent and Trademark Office (USPTO) has granted the company’s US Patent Application No. 18/113,458, which covers the….
